Literature DB >> 9576746

Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.

O Asai1, D L Longo, Z G Tian, R L Hornung, D D Taub, F W Ruscetti, W J Murphy.   

Abstract

Bone marrow transplantation (BMT) is currently used for the treatment of a variety of neoplastic diseases. However, significant obstacles limiting the efficacy of allogeneic BMT are the occurrence of graft-versus-host disease (GvHD) and tumor relapse. Natural killer (NK) cells exert a variety of immunologic and homoeostatic functions. We examined whether adoptive transfer of activated NK cells of donor type would prevent GvHD after allogeneic BMT in mice. Lethally irradiated C57BL/6 (H-2(b)) mice, were transplanted with MHC incompatible BALB/c (H-2(d)) bone marrow cells and spleen cells and rapidly succumbed to acute GvHD. In contrast, mice that also received activated NK cells of donor type exhibited significant increases in survival. In determining the mechanism by which the NK cells prevented GvHD, mice were concurrently treated with a neutralizing antibodies to the immunosuppressive cytokine TGFbeta. Anti-TGFbeta completely abrogated the protective effects of the activated donor NK cells indicating that TGFbeta plays an important role in the prevention of GvHD by NK cells. We then examined whether activated NK cells of donor type after allogeneic BMT would induce graft-versus-tumor (GvT) effects without GvHD in mice bearing a murine colon adenocarcinoma (MCA-38). 10 d after receiving the tumor, in which the mice had demonstrable lung metastases, recipients received an allogeneic BMT with or without activated NK cells. Administration of activated NK cells resulted in significant GvT effects after allogeneic BMT as evidenced by increases in median survival and fewer lung metastasis. No evidence of GVHD was detected compared with recipients receiving spleen cells alone which also developed fewer lung metastases but in which all had succumbed to GVHD. Thus, our findings suggest that adoptive immunotherapy using activated donor NK cells combined with allogeneic BMT inhibits GvHD and promotes GvT in advanced tumor-bearing mice. These results also suggest that GvT and GvHD can be dissociable phenomena.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9576746      PMCID: PMC508768          DOI: 10.1172/JCI1268

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  24 in total

Review 1.  Graft-versus-host disease.

Authors:  J L Ferrara; H J Deeg
Journal:  N Engl J Med       Date:  1991-03-07       Impact factor: 91.245

2.  Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.

Authors:  J M Goldman; R P Gale; M M Horowitz; J C Biggs; R E Champlin; E Gluckman; R G Hoffmann; S J Jacobsen; A M Marmont; P B McGlave
Journal:  Ann Intern Med       Date:  1988-06       Impact factor: 25.391

3.  Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor.

Authors:  L J Levitt; A Nagler; F Lee; J Abrams; M Shatsky; D Thompson
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

4.  Antibodies to IFN-gamma prevent immunologically mediated intestinal damage in murine graft-versus-host reaction.

Authors:  A M Mowat
Journal:  Immunology       Date:  1989-09       Impact factor: 7.397

5.  Monoclonal antibodies recognizing transforming growth factor-beta. Bioactivity neutralization and transforming growth factor beta 2 affinity purification.

Authors:  J R Dasch; D R Pace; W Waegell; D Inenaga; L Ellingsworth
Journal:  J Immunol       Date:  1989-03-01       Impact factor: 5.422

6.  In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice.

Authors:  S Habu; H Fukui; K Shimamura; M Kasai; Y Nagai; K Okumura; N Tamaoki
Journal:  J Immunol       Date:  1981-07       Impact factor: 5.422

7.  Graft-versus-leukaemia activity can be predicted by natural cytotoxicity against leukaemia cells.

Authors:  B Glass; L Uharek; M Zeis; H Loeffler; W Mueller-Ruchholtz; W Gassmann
Journal:  Br J Haematol       Date:  1996-05       Impact factor: 6.998

8.  Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells.

Authors:  M Sykes; M L Romick; D H Sachs
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

9.  Systemic interleukin-2 therapy in children with progressive neuroblastoma after high dose chemotherapy and bone marrow transplantation.

Authors:  M C Favrot; D Floret; S Negrier; P Cochat; E Bouffet; D C Zhou; C R Franks; T Bijman; M Brunat-Mentigny; I Philip
Journal:  Bone Marrow Transplant       Date:  1989-09       Impact factor: 5.483

Review 10.  Biology of natural killer cells.

Authors:  G Trinchieri
Journal:  Adv Immunol       Date:  1989       Impact factor: 3.543

View more
  82 in total

Review 1.  Molecular and cellular mechanisms of donor cell-induced tolerance.

Authors:  James F George; Leonik Ahumada; Ailing Lu
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 2.  Umbilical cord blood immunology: relevance to stem cell transplantation.

Authors:  Syh-Jae Lin; Dah-Chin Yan; Yen-Chang Lee; Hsiu-Shan Hsiao; Pei-Tzu Lee; Yu-Wen Liang; Ming-Ling Kuo
Journal:  Clin Rev Allergy Immunol       Date:  2012-02       Impact factor: 8.667

Review 3.  Progress in haploidentical stem cell transplantation.

Authors:  Ulas D Bayraktar; Richard E Champlin; Stefan O Ciurea
Journal:  Biol Blood Marrow Transplant       Date:  2011-08-09       Impact factor: 5.742

4.  Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells.

Authors:  Isabel Barao; Alan M Hanash; William Hallett; Lisbeth A Welniak; Kai Sun; Doug Redelman; Bruce R Blazar; Robert B Levy; William J Murphy
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-27       Impact factor: 11.205

Review 5.  Lymphoid reconstruction and vaccines.

Authors:  Ronald E Gress; Krishna V Komanduri; Hermann Einsele; Laurence J N Cooper
Journal:  Biol Blood Marrow Transplant       Date:  2007-01       Impact factor: 5.742

6.  Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity.

Authors:  Kai Sun; Danice E C Wilkins; Miriam R Anver; Thomas J Sayers; Angela Panoskaltsis-Mortari; Bruce R Blazar; Lisbeth A Welniak; William J Murphy
Journal:  Blood       Date:  2005-06-16       Impact factor: 22.113

7.  Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors.

Authors:  Andreas Lundqvist; J Philip McCoy; Leigh Samsel; Richard Childs
Journal:  Blood       Date:  2006-12-19       Impact factor: 22.113

8.  Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation.

Authors:  Junli Yu; Jeffrey M Venstrom; Xiao-Rong Liu; James Pring; Reenat S Hasan; Richard J O'Reilly; Katharine C Hsu
Journal:  Blood       Date:  2009-01-28       Impact factor: 22.113

Review 9.  Immune regulatory cell infusion for graft-versus-host disease prevention and therapy.

Authors:  Bruce R Blazar; Kelli P A MacDonald; Geoffrey R Hill
Journal:  Blood       Date:  2018-05-04       Impact factor: 22.113

10.  In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity.

Authors:  Ryosei Nishimura; Jeanette Baker; Andreas Beilhack; Robert Zeiser; Janelle A Olson; Emanuela I Sega; Mobin Karimi; Robert S Negrin
Journal:  Blood       Date:  2008-06-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.